Blair William & Co. IL Sells 300,760 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Blair William & Co. IL cut its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 39.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 457,570 shares of the biotechnology company's stock after selling 300,760 shares during the quarter. Blair William & Co. IL owned 0.16% of Exelixis worth $15,237,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. NEOS Investment Management LLC grew its holdings in Exelixis by 21.4% during the 4th quarter. NEOS Investment Management LLC now owns 49,256 shares of the biotechnology company's stock valued at $1,640,000 after buying an additional 8,674 shares during the last quarter. Elo Mutual Pension Insurance Co purchased a new stake in Exelixis during the 4th quarter worth $606,000. Meiji Yasuda Asset Management Co Ltd. purchased a new position in shares of Exelixis during the 4th quarter valued at approximately $234,000. Prudential Financial Inc. increased its holdings in Exelixis by 479.0% in the fourth quarter. Prudential Financial Inc. now owns 113,965 shares of the biotechnology company's stock valued at $3,926,000 after buying an additional 94,283 shares during the last quarter. Finally, Crowley Wealth Management Inc. bought a new position in shares of Exelixis in the 4th quarter worth about $50,000. Hedge funds and other institutional investors own 85.27% of the company's stock.

Exelixis Trading Up 1.0 %

EXEL stock traded up $0.38 during midday trading on Wednesday, hitting $36.77. The stock had a trading volume of 562,935 shares, compared to its average volume of 2,139,856. The stock has a 50-day simple moving average of $35.72 and a 200 day simple moving average of $33.46. Exelixis, Inc. has a 52 week low of $20.14 and a 52 week high of $40.02. The firm has a market capitalization of $10.29 billion, a price-to-earnings ratio of 20.77, a P/E/G ratio of 1.13 and a beta of 0.57.

Remove Ads

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. On average, equities analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current year.

Analyst Ratings Changes

Several research firms recently commented on EXEL. Stifel Nicolaus raised their target price on Exelixis from $30.00 to $36.00 and gave the company a "hold" rating in a research report on Wednesday, February 12th. Piper Sandler boosted their price target on shares of Exelixis from $37.00 to $38.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. Stephens restated an "equal weight" rating and set a $29.00 price target on shares of Exelixis in a report on Wednesday, February 12th. Morgan Stanley upgraded Exelixis from an "equal weight" rating to an "overweight" rating and boosted their target price for the company from $30.00 to $40.00 in a research note on Monday, January 27th. Finally, Brookline Capital Management initiated coverage on shares of Exelixis in a research note on Monday, December 23rd. They set a "buy" rating on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $37.59.

Insider Buying and Selling

In other news, EVP Patrick J. Haley sold 52,636 shares of the company's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the transaction, the executive vice president now directly owns 303,310 shares in the company, valued at approximately $11,216,403.80. This represents a 14.79 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jack L. Wyszomierski sold 8,768 shares of Exelixis stock in a transaction on Friday, February 28th. The shares were sold at an average price of $37.80, for a total value of $331,430.40. Following the completion of the sale, the director now directly owns 356,605 shares of the company's stock, valued at $13,479,669. This trade represents a 2.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 140,343 shares of company stock worth $5,177,234 in the last three months. Insiders own 2.85% of the company's stock.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.